A Phase 1/2 interventional study of IVW-1001 Ophthalmic Eyelid Wipe 0.1% and IVW-1001 Ophthalmic Eyelid Wipe 0.2% in Dry Eye Disease, sponsored by IVIEW Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by IVIEW Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 139th largest by enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 17 in phase 1/2, and was the 464th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 32 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
IVIEW Therapeutics Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
IVIEW Therapeutics Inc. has 3 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
This is a randomized (1:1:1), multicenter, parallel, vehicle-controlled, double-masked study to evaluate the safety, tolerability, and efficacy of IVW-1001 Ophthalmic Eyelid Wipes in subjects with DED. Treatments will be IVW-1001 Ophthalmic Eyelid Wipe 0.2% (high dose), IVW 1001 0.1% (low dose), or IVW-1001 Ophthalmic Eyelid Wipe Placebo (vehicle). Subjects will participate in a 7-day, run-in period followed by a 28-daydosing period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Vehicle
Drug: IVW-1001 Placebo
IVW-1001 Ophthalmic Eyelid Wipe 0.1%
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
IVW-1001 Placebo
Schirmer's
Mean change from baseline in study eye in unanesthetized measure of tear product using Schirmer strip (measured in mm of wetness)
Time frame: 29 Days
Visual Acuity
Mean change from baseline in best corrected visual acuity
Time frame: 29 Days
Total Corneal Fluorescein Staining Score in the Study Eye
Change from baseline in score on a scale (0 - none - to 20 - severe)
Time frame: Week 4
Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score
Change from Baseline in the SANDE visual analog scale (0 - none to 100 - severe)
Time frame: Week 4
Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score
Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)
Time frame: 4 weeks
Symptom Assessment in Dry Eye (SANDE): Global Score
Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)
Time frame: 4 weeks
| Milestone | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Started | 53 | 48 | 49 |
| Completed | 53 | 48 | 49 |
| Not completed | 0 | 0 | 0 |
Mean change from baseline in study eye in unanesthetized measure of tear product using Schirmer strip (measured in mm of wetness)
| mm | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Schirmer's | 1.3 ± 6.40 | 2.1 ± 6.64 | 0.9 ± 5.24 |
Mean change from baseline in best corrected visual acuity
| Logarithm of Minimum Angle of Resolution | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Visual Acuity | -0.007 ± 0.0739 | -0.013 ± 0.0625 | -0.014 ± 0.0728 |
Change from baseline in score on a scale (0 - none - to 20 - severe)
| Score on a scale | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Total Corneal Fluorescein Staining Score in the Study Eye | -1.65 ± 0.24 | -1.80 ± 0.25 | -1.10 ± 0.25 |
Change from Baseline in the SANDE visual analog scale (0 - none to 100 - severe)
| Score on a scale | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score | -5.77 ± 2.91 | -23.57 ± 3.06 | -9.88 ± 3.08 |
Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)
| Score on a scale | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score | -8.73 ± 2.78 | -22.80 ± 2.93 | -12.55 ± 2.94 |
Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)
| Score on a scale | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Symptom Assessment in Dry Eye (SANDE): Global Score | -7.11 ± 2.70 | -23.36 ± 2.84 | -11.16 ± 2.86 |
Collected over Week 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IVW-1001 0.1% | 0/53 (0%) | 0/53 (0%) | 3/53 (5.7%) |
| IVW-1001 0.2% | 0/48 (0%) | 0/48 (0%) | 5/48 (10.4%) |
| IVW-1001 Placebo | 0/49 (0%) | 0/49 (0%) | 4/49 (8.2%) |
| Event | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo |
|---|---|---|---|
| Eye disordersEye disorders | 3/53 | 5/48 | 4/49 |
| Age, Continuous(years) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 11.19 | 63.5 ± 12.07 | 68.1 ± 11.43 | 65.1 ± 11.57 |
| Sex: Female, Male(Participants) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Female | 36 | 38 | 39 | 113 |
| Male | 17 | 10 | 10 | 37 |
| Race (NIH/OMB)(Participants) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 15 | 11 | 16 | 42 |
| White | 36 | 34 | 31 | 101 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| United States | 53 | 48 | 49 | 150 |
| Unanesthetized Schirmer test (Study Eye)(mm) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Mean | 6.8 ± 1.98 | 6.1 ± 1.87 | 6.7 ± 1.92 | 6.5 ± 1.93 |
| Total Corneal Fluorescein Staining Score in the Study Eye (0, none to 20, severe)(Score on a scale) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Mean | 6.5 ± 1.37 | 6.8 ± 1.72 | 6.8 ± 1.48 | 6.7 ± 1.53 |
| Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score (0, none, to 100, severe)(Score on a scale) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Mean | 61.1 ± 23.3 | 62.6 ± 21.1 | 61.9 ± 23.0 | 61.8 ± 22.5 |
| Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score(Score on a scale) | IVW-1001 0.1% | IVW-1001 0.2% | IVW-1001 Placebo | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 23.1 | 54.0 ± 20.2 | 55.0 ± 22.5 | 54.6 ± 21.9 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Oct 2024, 3 months.
Results were first posted in Feb 2026, 1 year 3 months after primary completion.
Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IVW-1001
IVIEW Therapeutics Inc.